Who
Angela M. Cacace
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Arvinas.
In numbers
- Trades disclosed
- 23
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $518K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 Jun 2024
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $20K2,576 at $7.60 | filing |
| 17 Jun 2026filed 18 Jun 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $20K2,576 at $7.60 | filing |
| 11 May 2026filed 13 May 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $96K9,657 at $9.94 | filing |
| 11 May 2026filed 13 May 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $96K9,657 at $9.94 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $13K1,038 at $12.16 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $31K2,571 at $12.16 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $13K1,038 at $12.16 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $31K2,571 at $12.16 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $55K4,592 at $11.89 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $55K4,592 at $11.89 | filing |
| 17 Jun 2025filed 18 Jun 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $19K2,583 at $7.49 | filing |
| 9 May 2025filed 13 May 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —91,000 at $0.00 | filing |
| 9 May 2025filed 13 May 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —59,600 at $0.00 | filing |
| 24 Feb 2025filed 25 Feb 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $51K3,061 at $16.75 | filing |
| 24 Feb 2025filed 25 Feb 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $19K1,146 at $16.55 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,960 at $0.00 | filing |
News
Financial Comparison: Arvinas (NASDAQ:ARVN) & Geron (NASDAQ:GERN)ARVN · tickerreport.com · 20 Oct 2026
0 headlines in the last 90 days name Angela M. Cacace; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.